Integrative proteomics reveals MSH6 to modulate PARP inhibitor sensitivity in BRCA1/2-proficient ovarian cancer
Ou Deng, Thales Da Costa Nepomuceno, Bin Fang, Eric A Welsh, Victoria Izumi, Rachael H Martin, Erin M George, John M Koomen · 2026
Read Integrative proteomics reveals MSH6 to modulate PARP inhibitor sensitivity in BRCA1/2-proficient ovarian cancer by Ou Deng, Thales Da Costa Nepomuceno, Bin Fang, Eric A Welsh, Victoria Izumi, Rachael H Martin, Erin M George, John M Koomen (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0357365.txt.
Description
Ou Deng and a team of cancer researchers hunt for a puzzle. Some ovarian tumors respond to a class of drugs that block DNA repair. They respond even when the usual genetic markers say they should not. Tumors lacking two famous repair genes respond well, yet some tumors with working copies respond too. The team compared sensitive and resistant lab-grown tumor cells, mapping which proteins cluster with the drug's target.
Sensitive cells carried more of a mismatch-repair protein in that cluster, and lowering that protein made cells less sensitive to the drug. A partner protein also behaved differently after treatment, and lowering it restored sensitivity. Deng and colleagues propose their protein pair as a clue for widening the group of patients who might benefit.
Catalog record
| CREATOR | Ou Deng, Thales Da Costa Nepomuceno, Bin Fang, Eric A Welsh, Victoria Izumi, Rachael H Martin, Erin M George, John M Koomen |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 57817 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |